Document Detail

Management of dyslipidemia in patients with complicated metabolic syndrome.
MedLine Citation:
PMID:  16098839     Owner:  NLM     Status:  MEDLINE    
As the prevalence of the metabolic syndrome increases, 2 comorbid conditions--hepatic steatosis and human immunodeficiency virus (HIV) lipodystrophy--have become difficult clinical challenges. Dyslipidemia in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis may improve with use of statins, fibrates, niacin, and thiazolidinediones, but the data are presently very limited. HIV lipodystrophy is associated with a marked risk of coronary artery disease (CAD), and more aggressive management of the dyslipidemia is likely necessary to improve the prognosis.
Michael H Davidson
Related Documents :
9827279 - Rapidly evolving hepatitis c virus-related cirrhosis in a human immunodeficiency virus-...
16990829 - Therapy insight: cns manifestations of hiv-associated immune reconstitution inflammator...
20947819 - Differential effects of rosiglitazone and metformin on postprandial lipemia in patients...
12531329 - Therapeutic vaccination for future management of hiv/aids.
16545639 - Functional and structural markers of atherosclerosis in human immunodeficiency virus-in...
17922559 - Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepati...
15566899 - Inhibition of syncytia-inducing (si) virus by autologous serum from hiv-1-infected indi...
1655869 - A prospective study of posttransfusion hepatitis in taiwan.
18085869 - Hiv infection affects parietal-dependent spatial cognition: evidence from mental rotati...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The American journal of cardiology     Volume:  96     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2005 Aug 
Date Detail:
Created Date:  2005-08-15     Completed Date:  2005-09-29     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  22E-25E     Citation Subset:  AIM; IM    
Division of Preventive Cardiology, Department of Medicine, Rush University Medical Center, Chicago, Illinois 60612, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Clofibric Acid / therapeutic use*
Fatty Liver / complications
HIV-Associated Lipodystrophy Syndrome / complications
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Hyperlipidemias / drug therapy*
Metabolic Syndrome X / complications*
Niacin / therapeutic use*
Thiazolidinediones / therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Thiazolidinediones; 59-67-6/Niacin; 882-09-7/Clofibric Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Approach to treatment of the patient with metabolic syndrome: lifestyle therapy.
Next Document:  Lipid management in patients with diabetes mellitus.